Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 21, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, January 20, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Carter Gould Maintained (BIIB) at Hold with Decreased Target to $244 on, Jan 20th, 2022
Carter Gould of Barclays, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $280 to $244 on, Jan 20th, 2022.
Carter has made no other calls on BIIB in the last 4 months.
There are 20 other peers that have a rating on BIIB. Out of the 20 peers that are also analyzing BIIB, 11 agree with Carter's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
- Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
- Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
- Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $275 on, Thursday, December 23rd, 2021
- Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
- Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021
- Mohit Bansal of "Wells Fargo" Initiated at Hold and Held Target at $250 on, Thursday, December 9th, 2021
- Salveen Richter of "Goldman Sachs" Initiated at Hold and Held Target at $271 on, Monday, December 6th, 2021
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, November 19th, 2021
- Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $327 on, Friday, October 15th, 2021
These are the ratings of the 9 analyists that currently disagree with Carter
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $360 on, Tuesday, January 18th, 2022
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $292 on, Wednesday, January 12th, 2022
- Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $350 on, Wednesday, December 22nd, 2021
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $325 on, Monday, December 20th, 2021
- Evan Seigerman of "BMO Capital" Initiated at Buy and Held Target at $315 on, Friday, November 19th, 2021
- Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $375 on, Thursday, October 21st, 2021
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $344 on, Friday, October 15th, 2021
- Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021
